VIDEO: MCO-010 for retinitis pigmentosa improves vision in phase 2b/3 study
Click Here to Manage Email Alerts
In this Healio Video Perspective from the ASRS meeting, Michael A. Singer, MD, of the University of Texas Health Science Center in San Antonio, discusses topline results for MCO-010 for the treatment of retinitis pigmentosa.
The phase 2b/3 RESTORE study investigated two doses of the optogenetic therapy from Nanoscope Therapeutics compared with sham and looked at the changes in vision from baseline to 52 weeks as the primary endpoint. Secondary endpoints included vision changes at 76 weeks, safety, shape discrimination and mobility testing.
The study “achieved its primary and secondary endpoint with statistical significance and no serious adverse events,” Singer said. “This is clinically meaningful visual improvement in these legally blind individuals who have progressive and permanent neurodegeneration of the retina, and the visual improvement at 2 years demonstrates that it’s durable.”
Collapse
Singer M. BCVA analysis of low- or high-dose MCO-010 optogenetic therapy for retinitis pigmentosa: First time 100-week topline results from a phase 2b/3 clinical trial (RESTORE). Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Read more about
Click Here to Manage Email Alerts